Please provide your email address to receive an email when new articles are posted on . With the rise of hospitalists, in an inpatient setting, this process is often handled and overseen by hospital ...
Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
Incidence and survival outcomes of breast cancer subtypes in the United States. MRT identification of previously undocumented medications with DDI potential (n=235).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results